A small bit of encouragement.
VJHEMONC video - Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses data from the Phase III POLARIX study (NCT03274492) which evaluated polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone